Clindacin® B Prolong (Clindacin B prolong)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceButoconazole + ClindamycinButoconazole + Clindamycin
Similar drugsTo uncover
  • Clindacin® B Prolong
    cream
    AKRIKHIN HFK, JSC     Russia
    • Dosage form: & nbspThe cream is vaginal.
    Composition:
    100 g of cream contain:

    active substances: butoconazole nitrate in terms of 100% substance - 2 g; clindamycin phosphate in terms of 100% substance - 2,376 g, equivalent to 2g of clindamycin;

    Excipients: Euxyl PE 9010 Preservative (phenoxyethanol, 90%, 10% etilgeksilglitserol) - 0, 5 g, equivalent to 0.45 g of phenoxyethanol, propylene glycol - 5 g isopropyl myristate - 8 g, tsetostearat macrogol (macrogol 20-cetostearyl ether) - 2 g of cetostearyl alcohol [60% cetyl alcohol, stearyl alcohol 40%] - 6 g, gidroksipropildikrahmalfosfat - 8 g sodium hydroxide - 0.26 g purified water -up to 100 g
    Pharmacotherapeutic group:Antimicrobial and antifungal agent.
    ATX: & nbsp

    G.01   Antiseptics and antimicrobials for the treatment of gynecological diseases

    Pharmacodynamics:Butoconazole - imidazole derivatives have fungicidal activity against fungi Candida, Trichophyton, Microsporum, Epidermaphyton and some gram-positive bacteria. The most effective in candidiasis. Blocking the formation of ergosterol from the lanosterol in the cell membrane increases the permeability of the membrane, which leads to lysis of the fungal cell. Clindamycin - bacteriostatic antibiotic from the group of lincosamides,has a broad spectrum, it binds to the 50S ribosomal subunit and membrane inhibits protein synthesis in the bacterial cell. With respect to a number of gram-positive cocci, a bactericidal effect is possible. In in vitro conditions susceptible to clindamycin following microorganisms causing bacterial vaginosis: Gardnerella vaginalis, Mobiluncus spp, Mycoplasma hominis, Bacteroides spp, Peptostreptococcus spp...

    The hydrophilic cream base provides the gel-like consistency at a temperature of 35-40 ° C. In intravaginal application, the cream does not melt, and therefore the active agents are in the mucosa of the vagina for 1-3 days. There is cross-resistance between clindamycin and lincomycin.
    Form release / dosage:Vaginal cream 2% + 2%.
    Packaging:
    • Tubes aluminum (1) / complete with applicator / - packs cardboard
    Storage conditions:At a temperature of 15-25 degrees.
    Shelf life:2 years.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-001855
    Date of registration:27.09.2012/12.10.2015
    Date of cancellation:2017-09-27
    The owner of the registration certificate:AKRIKHIN HFK, JSC AKRIKHIN HFK, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp07.04.2016
    Illustrated instructions
      Instructions
      Up